Gastrointestinal stromal tumors: past, present, and future
Author:
- 23 July 2008
- journal article
- review article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 43 (7) , 499-508
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. The name “GIST” was proposed in 1983, but the cell origin of GIST remained unclear until 1998, when my colleagues and I reported immunohistochemical evidence that GIST originated from interstitial cells of Cajal or their precursors. At the same time, we reported gain-of-function mutations of the Kit gene in GISTs. The Kit gene encodes KIT receptor tyrosine kinase, whose structure is similar to that of platelet-derived growth factor receptor (PDGFR). Imatinib mesylate was initially developed as an inhibitor of PDGFR. Then, it was found to be a potent inhibitor of BCR-ABL. Imatinib was successfully used for the treatment of chronic myeloid leukemia. When we reported gain-of-function mutations of the Kit gene in GISTs, the inhibitory effect of imatinib on KIT was already known. Imatinib was then successfully applied to the treatment of GISTs. The interrelationship between the type of Kit gain-of-function mutation and the therapeutic effect of imatinib has been well characterized in GISTs. Although various mutations of Kit and Pdgfr-α genes have been found in GISTs, most GISTs are luckily imatinibsensitive. After long-term administration of imatinib, however, new imatinib-resistant clones develop a secondary mutation of the Kit or Pdgfr-α gene. New drugs and adjuvant regimens against such secondary progression are now being intensively explored.Keywords
This publication has 104 references indexed in Scilit:
- Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomachJournal of Clinical Investigation, 2007
- Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumorProceedings of the National Academy of Sciences, 2006
- Combined Surgical and Molecular TherapyAnnals of Surgery, 2006
- Novel NF1 gene mutation in a Japanese patient with neurofibromatosis type 1 and a gastrointestinal stromal tumorJournal of Gastroenterology, 2006
- Mast Cell-Deficient W-sash c-kit Mutant KitW-sh/W-sh Mice as a Model for Investigating Mast Cell Biology in VivoThe American Journal of Pathology, 2005
- Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumorsJournal of Gastroenterology, 2005
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Gastric stromal tumors Reappraisal of histogenesisAmerican Journal of Surgical Pathology, 1983